Exosome-mediated delivery of inflammation-responsive <i>Il-10</i> mRNA for controlled atherosclerosis treatment

Bu, Te; Li, Zhelong; Hou, Ying; Sun, Wenqi; Zhang, Rongxin; Zhao, Lianbi; Wei, Mengying; Yang, Guodong; Yuan, Lijun

doi:10.7150/thno.64229

Cited by 53 publications

(34 citation statements)

References 45 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes loaded with IL-10 mRNA were engineered to target inflamed macrophages in the atherosclerotic lesion. These exosomes were used to treat Apoe −/− mice under 8 weeks high fat diet and resulted in decreased atherosclerotic plaque formation compared to PBS receiving control or exosome treatment ( 157 ).…”

Section: Cytokinesmentioning

confidence: 99%

Inflammatory Mediators in Atherosclerotic Vascular Remodeling

Evans

Yerly

Vorst

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atherosclerotic vascular disease remains the most common cause of ischemia, myocardial infarction, and stroke. Vascular function is determined by structural and functional properties of the arterial vessel wall, which consists of three layers, namely the adventitia, media, and intima. Key cells in shaping the vascular wall architecture and warranting proper vessel function are vascular smooth muscle cells in the arterial media and endothelial cells lining the intima. Pathological alterations of this vessel wall architecture called vascular remodeling can lead to insufficient vascular function and subsequent ischemia and organ damage. One major pathomechanism driving this detrimental vascular remodeling is atherosclerosis, which is initiated by endothelial dysfunction allowing the accumulation of intimal lipids and leukocytes. Inflammatory mediators such as cytokines, chemokines, and modified lipids further drive vascular remodeling ultimately leading to thrombus formation and/or vessel occlusion which can cause major cardiovascular events. Although it is clear that vascular wall remodeling is an elementary mechanism of atherosclerotic vascular disease, the diverse underlying pathomechanisms and its consequences are still insufficiently understood.

show abstract

Section: Cytokinesmentioning

confidence: 99%

Inflammatory Mediators in Atherosclerotic Vascular Remodeling

Evans

Yerly

Vorst

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Breast cancer cell-derived exosomes were used to deliver S100A4 siRNA that led to significantly reduced postoperative breast cancer metastasis ( 121 ), and exosomes loaded with SCD-1 siRNA significantly promoted anaplastic thyroid carcinoma cell apoptosis by enhancing its intracellular ROS level ( 122 ). Exosomes loaded with mRNAs encoding SARS-CoV-2 spike and nucleocapsid proteins triggered long-lasting immune response both in vitro and in vivo ( 123 ), and exosome-mediated delivery of IL10 mRNA effectively alleviated atherosclerosis ( 124 ). Exosome-transmitted lncRNA SENP3-EIF4A1 suppressed the progression of hepatocellular cancer cells ( 125 ), and exosome-delivered lncRNA PTENP1 inhibited the development of bladder cancer cells ( 27 ).…”

Section: Exosome For Onco-therapeuticsmentioning

confidence: 99%

Emerging innovations on exosome-based onco-therapeutics

Dai

2022

Front. Immunol.

View full text Add to dashboard Cite

Exosomes, nano-sized extracellular vesicles for intercellular communications, are gaining rapid momentum as a novel strategy for the diagnosis and therapeutics of a spectrum of diseases including cancers. Secreted by various cell sources, exosomes pertain numerous functionalities from their parental cells and have enhanced stability that enable them with many features favorable for clinical use and commercialization. This paper focuses on the possible roles of exosomes in cancer therapeutics and reviews current exosome-based innovations toward enhanced cancer management and challenges that limit their clinical translation. Importantly, this paper casts insights on how cold atmospheric plasma, an emerging anticancer strategy, may aid in innovations on exosome-based onco-therapeutics toward improved control over cancers.

show abstract

“…Stimuli-responsive drug release is a pivotal strategy in current drug delivery research due to the “smart” drug release behaviors of certain types of nanomedicines at predictable locations in response to local (i.e., physiological or pathophysiological) cues, including pH, redox, hypoxia, glucose, and enzymes, or in response to external stimuli, such as light, ultrasound, magnetic fields, electric fields, and temperature [ 59 , 60 , 61 , 62 , 63 , 64 ]. These so-called “smart” therapeutics mainly depend on hydrolysis-controlled release systems.…”

Section: Physicochemical Impact On Delivery Efficiencymentioning

confidence: 99%

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Jin

2022

Pharmaceutics

View full text Add to dashboard Cite

Undesirable side effects and multidrug resistance are the major obstacles in conventional chemotherapy towards cancers. Nanomedicines provide alternative strategies for tumor-targeted therapy due to their inherent properties, such as nanoscale size and tunable surface features. However, the applications of nanomedicines are hampered in vivo due to intrinsic disadvantages, such as poor abilities to cross biological barriers and unexpected off-target effects. Fortunately, biomimetic nanomedicines are emerging as promising therapeutics to maximize anti-tumor efficacy with minimal adverse effects due to their good biocompatibility and high accumulation abilities. These bioengineered agents incorporate both the physicochemical properties of diverse functional materials and the advantages of biological materials to achieve desired purposes, such as prolonged circulation time, specific targeting of tumor cells, and immune modulation. Among biological materials, mammalian cells (such as red blood cells, macrophages, monocytes, and neutrophils) and pathogens (such as viruses, bacteria, and fungi) are the functional components most often used to confer synthetic nanoparticles with the complex functionalities necessary for effective nano-biointeractions. In this review, we focus on recent advances in the development of bioinspired and biomimetic nanomedicines (such as mammalian cell-based drug delivery systems and pathogen-based nanoparticles) for targeted cancer therapy. We also discuss the biological influences and limitations of synthetic materials on the therapeutic effects and targeted efficacies of various nanomedicines.

show abstract

Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment

Cited by 53 publications

References 45 publications

Inflammatory Mediators in Atherosclerotic Vascular Remodeling

Inflammatory Mediators in Atherosclerotic Vascular Remodeling

Emerging innovations on exosome-based onco-therapeutics

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Contact Info

Product

Resources

About